ArticleEnvironmental research2025
Associations between gestational polybrominated diphenyl ether (PBDE) serum concentrations and child sleep outcomes from ages 2-8 years.
Article in Environmental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Gestational polybrominated diphenyl ethers (PBDEs) exposures have been associated with thyroid disruption in pregnant women and adverse neurobehavioral outcomes in their children, but it is unknown if they interfere with children's sleep patterns. We assessed gestational PBDE exposure (16 weeks) and child sleep patterns from ages 2-8 years using 410 mother-child dyads in the Health Outcomes and Measures of the Environment (HOME) Study. Gestational biomarkers of serum PBDEs include PBDE-153 (GM ± GSD: 5.2 ± 2.8 ng/g lipid), PBDE-100 (4 ± 2.6), PBDE-99 (4.6 ± 2.7), PBDE-47 (20.2 ± 2.6), PBDE-28 (1.3 ± 2.2), and ΣPBDEs (37.03 ± 2.52). We measured child sleep patterns using the adapted Child Sleep Health Questionnaire, which includes sleep irregularity (mean ± SD: 2.5 ± 0.8), hypersomnolence (4.7 ± 1.5), sleep disruption (6.7 ± 1.6), and sleep duration. We assessed longitudinal associations between gestational PBDEs and sleep patterns using generalized estimating equations, adjusting for covariates. For PBDE-visit interactions (p < 0.1), visit-specific estimates with 95 % CIs were calculated; otherwise, the overall estimate was reported. Every 10-fold increase in PBDE-99 (β = 0.18, 95 % CI: 0.04, 0.23), PBDE-47 (0.15, 95 % CI: 0.001, 0.3) and ΣPBDEs (0.13, 95 % CI: 0.21, 0.27) was associated with increased sleep irregularity for all years, and PBDE-28 was associated with this outcome at age 5 and 8 years (0.43, 95 % CI: 0.09, 0.77). PBDE-153 (-0.5, 95 % CI: 1.06, 0.05) was associated with decreased hypersomnolence at age 4 years. PBDE-47 (0.3, 95 % CI: 0.004, 0.61), PBDE-99 (0.38, 95 % CI: 0.1, 0.67 and 0.62), and ΣPBDEs (0.27, 95 % CI: 0.02, 0.56) were associated with increased sleep disruption for all ages. We observed no significant associations between PBDEs and sleep duration. We found that gestational PBDEs were associated with sleep irregularity and sleep disruption in children, highlighting the need to explore sleep as a mediator of PBDE-associated neurobehavioral problems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.